Khiron Life Sciences Corp.
KHRNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.04 | 0.24 | -0.02 |
| FCF Yield | -64.53% | -59.90% | -33.89% | -25.19% |
| EV / EBITDA | -0.86 | -1.16 | -2.77 | -3.35 |
| Quality | ||||
| ROIC | -54.08% | -35.41% | -50.59% | -58.91% |
| Gross Margin | 49.79% | 87.42% | 25.42% | 33.35% |
| Cash Conversion Ratio | 0.61 | 1.02 | 0.83 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.12% | 107.94% | – | – |
| Free Cash Flow Growth | 18.66% | 24.73% | -94.46% | -87,202.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.83 | 0.16 | 0.68 |
| Interest Coverage | -44.47 | -50.44 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.68 | 0.12 | 7.43 | 2.49 |
| Cash Conversion Cycle | 374.54 | 958.76 | -169.10 | -2,614.23 |